Skip to main content
Neurology

Epilepsy Agent RAP-219 Shows Promising Safety, Target Occupancy Across Phase 1 Studies

An ongoing phase 2a study of RAP-219 involves adult patients with drug-resistant epilepsy who have an implanted responsive neurostimulation (RNS) device, allowing for real-time monitoring of intracranial EEG data.:

Source: Neurology Read More

Related Posts

Neurology <![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>

<![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>

April 21, 2026
Neurology <![CDATA[NMOSD Associated With Escalation to Rituximab, Elecsys NfL Test Receives European Approval, Neurology by the Numbers]]>

<![CDATA[NMOSD Associated With Escalation to Rituximab, Elecsys NfL Test Receives European Approval, Neurology by the Numbers]]>

April 20, 2026
Neurology <![CDATA[GLP-1 Receptor Agonists Show Translational Potential in Alzheimer Disease Despite Mixed Study Results]]>

<![CDATA[GLP-1 Receptor Agonists Show Translational Potential in Alzheimer Disease Despite Mixed Study Results]]>

April 20, 2026